Avita Medical Ltd (AVH) - Research

$0.470

AVH General Information +

ASX Code AVH
Website http://www.avitamedical.com
GICS Sub-Industry Biotechnology
Market Cap ($M) 876
Current Price $0.470
Day High $0.480
Day Low $0.465
Last Close $0.470
Price Movement - ( No change )
Prices as at 16:40, 24 May 2019
+Security prices are delayed by at least 20 minutes and are indicative only.

AVH Company Overview

Business Description

Avita Medical Ltd (AVH) is a medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of wounds, scars and skin defects. The company's products includes regenerative medicine products (ReCell Autologous Spray-On-Skin), ReGenercell and Renovacell.

AVH Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2020 F 0.00 -0.50 0.00% 0.00 0.00 0.00% 0.0%
2019 F 0.00 -1.60 0.00% 0.00 0.00 0.00% 0.0%
2018 A -16.48 -1.80 0.00% 0.00 0.00 0.00% 0.0%

AVH Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2018 A 2019 F 2020 F 2018 A 2019 F 2020 F 2018 A 2019 F 2020 F
Avita Medical (AVH) $886M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL (CSL) $93,431M 0.3775 0.1400 0.1291 39.2837 34.4591 30.5183 1.50% 1.32% 1.52%
Clinuvel Pharmaceuticals (CUV) $1,568M 0.8671 0.0000 0.0000 119.9251 0.0000 0.0000 0.06% 0.00% 0.00%
Mesoblast (MSB) $748M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

AVH Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 31.50 0.00
Market 0.67 14.40 1.19 1.03
Sector 1.03 25.30 3.27 2.12

AVH Directors

Name Position Start Date
Dr Michael S Perry Chief Executive Officer, Executive Director 6 Feb 2013
Mr Louis (Lou) James Panaccio Non-Executive Chairman, Non-Executive Director 1 Jul 2014
Professor Suzanne Crowe Non-Executive Director 13 Jan 2016
Mr Damien McDonald Non-Executive Director 13 Jan 2016
Mr Jeremy Curnock-Cook Non-Executive Director 19 Oct 2012
Mr Louis Drapeau Non-Executive Director 13 Jan 2016

AVH Management

Name Position
Timothy Rooney Chief Administrative Officer
Erin Liberto Chief Commercialization Officer
Dale Sander Chief Financial Officer
Kate Goland Joint Company Secretary
Mark Andrew Licciardo Joint Company Secretary
Andrew Quick SVP, Clinical Development

AVH Substantial Shareholders

Holding Name
246,465,803 (18.36%) HSBC Custody Nominees (Australia) Limited
207,985,797 (15.49%) HSBC Custody Nominees (Australia) Limited A/C 2

AVH Calendar of Events

Date Event
27 February 2020 Report (Interim)
30 October 2019 Report (Annual)
30 August 2019 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.